"A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM)."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).

TPS8056Background: Selinexor is an oral, selective inhibitor of nuclear export that specifically blocks exportin 1, leading to the nuclear accumulation & reactivation of tumor suppressor proteins. ... Click to show full abstract

Keywords: randomized controlled; bortezomib dexamethasone; controlled open; phase randomized; open label; dexamethasone

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended